CapeOX

Phase 3Small molecule

GSK

CapeOX is one of 163 small molecule programs targeting Neoadjuvant Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

162

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant TherapyRecruiting

Rectal CancerRecruiting

Locally-Advanced Rectal CancerRecruiting

Peripheral NeuropathyNot yet recruiting

ChemotherapyActive, not recruiting

Neoadjuvant ImmunotherapyRecruiting

Microsatellite StableRecruiting

Neoadjuvant TherapyPhase 2

Recruiting

Rectal CancerPhase 3

Recruiting

Locally-Advanced Rectal CancerPhase 2

Recruiting

Peripheral NeuropathyPhase 2

Not yet recruiting

ChemotherapyPhase 2

Active, not recruiting

Neoadjuvant ImmunotherapyPhase 2

Recruiting

Microsatellite StablePhase 2

Recruiting

Competition

Competitive Landscape

116 competitors in Chemotherapy

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

20 2

Eloxatin

Teva

Phase 3

14 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 4

Avastin

Roche

Phase 3

12 5

Cytosar

Teva

Phase 3

11 6

Imfinzi

AstraZeneca

Phase 3

8 7

Camptosar

Pfizer

Phase 3

8 8

Vepesid

AAvyxa

Phase 3

23 9

Opdivo

Bristol-Myers Squibb

Phase 3

7 10

Beyfortus

BeiGene

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Peripheral Neuropathy

NCT06722950

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT05576480

Phase 2Recruiting

Neoadjuvant Immunotherapy

NCT05515796

Q3 2027

Phase 3Recruiting

Rectal Cancer

NCT05201430

Phase 2Recruiting

Locally Advanced Colon Cancer

NCT06709885

Q2 2028

Phase 2/3Not yet recruiting

Locally-Advanced Rectal Cancer

NCT06443671

Clinical

Trials by Indication[1]

Colorectal Cancer3 trials

Window of Opportunity Study in Colorectal Cancer

Completed·NNational Cancer Centre, Singapore·Phase 2·NCT03984578·33 enrolled

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT06014372·55 enrolled

Apatinib for Resectable Colorectal Cancer

Withdrawn·—·N/A·NCT03228043

Locally-advanced Rectal Cancer3 trials

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Withdrawn·SShanghai Minimally Invasive Surgery Center·Phase 2·NCT04620473

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Recruiting·RRuijin Hospital·Phase 2·NCT05576480·55 enrolled

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2/3·NCT06443671·132 enrolled

Locally Advanced Colon Cancer2 trials

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

Unknown status·Ffan li·Phase 2·NCT05833672·100 enrolled

HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer

Recruiting·—·Phase 2·NCT06709885·100 enrolled

Rectal Cancer2 trials

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Recruiting·FFudan University·Phase 3·NCT05201430·300 enrolled

Online Adaptive Radiotherapy With a Boost to the Primary Tumor and Clinically Involved Lymph Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial

Active, not recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT06246344·128 enrolled

Neoadjuvant Therapy1 trial

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Recruiting·HHuazhong University of Science and Technology·Phase 2·NCT06516445·33 enrolled

7 more indications

Microsatellite Stable1 trial

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Recruiting· GSK logo

GSK·Phase 2·NCT06567782·120 enrolled

Peripheral Neuropathy1 trial

Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Not yet recruiting·SShandong New Time Pharmaceutical Co., LTD·Phase 2·NCT06722950·120 enrolled

Chemotherapy1 trial

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruiting·NNational Cancer Center Hospital East·Phase 1/2·NCT05394740·30 enrolled

Efficacy and Safety1 trial

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05068206·120 enrolled

Colon Cancer1 trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT05855200·892 enrolled

Capecitabine1 trial

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Completed· GSK logo

GSK·Phase 1·NCT00387387·50 enrolled

Neoadjuvant Immunotherapy1 trial

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Recruiting·—·Phase 2·NCT05515796·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for CapeOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CapeOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CapeOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

CapeOX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q2 2028

Trials by Indication[1]

Colorectal Cancer3 trials

Locally-advanced Rectal Cancer3 trials

Locally Advanced Colon Cancer2 trials

Rectal Cancer2 trials

Neoadjuvant Therapy1 trial

Microsatellite Stable1 trial

Peripheral Neuropathy1 trial

Chemotherapy1 trial

Efficacy and Safety1 trial

Colon Cancer1 trial

Capecitabine1 trial

Neoadjuvant Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News